Drug-repurposing against COVID-19 by targeting a key signaling pathway : An in silico study
Copyright © 2021 Elsevier Ltd. All rights reserved..
Currently, a plethora of information has been accumulated concerning COVID-19, including the transmission pathway of SARs-CoV-2. Thus, we retrieved targets associated with the development of COVID-19 via PubChem. A total of 517 targets were identified, and signaling pathways responded after infection of SARs-CoV-2 in humans constructed a bubble chart using RPackage. The bubble chart result suggested that the key signaling pathway against COVID-19 was the estrogen signaling pathway associated with AKT1, HSP90AB1, BCL2 targets. The three targets have the strongest affinity with three ligands-Akti-1/2, HSP990, S55746, respectively. In conclusion, this work provides three key elements to alleviate COVID-19 symptoms might be anti-inflammatory effects on SARs-CoV-2-infected lung cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:155 |
|---|---|
| Enthalten in: |
Medical hypotheses - 155(2021) vom: 27. Okt., Seite 110656 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Oh, Ki Kwang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AKT1-HSP90AB1-BCL2 |
|---|
| Anmerkungen: |
Date Completed 05.10.2021 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mehy.2021.110656 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329427962 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329427962 | ||
| 003 | DE-627 | ||
| 005 | 20231225205110.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mehy.2021.110656 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM329427962 | ||
| 035 | |a (NLM)34399157 | ||
| 035 | |a (PII)S0306-9877(21)00175-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Oh, Ki Kwang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug-repurposing against COVID-19 by targeting a key signaling pathway |b An in silico study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2021 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Currently, a plethora of information has been accumulated concerning COVID-19, including the transmission pathway of SARs-CoV-2. Thus, we retrieved targets associated with the development of COVID-19 via PubChem. A total of 517 targets were identified, and signaling pathways responded after infection of SARs-CoV-2 in humans constructed a bubble chart using RPackage. The bubble chart result suggested that the key signaling pathway against COVID-19 was the estrogen signaling pathway associated with AKT1, HSP90AB1, BCL2 targets. The three targets have the strongest affinity with three ligands-Akti-1/2, HSP990, S55746, respectively. In conclusion, this work provides three key elements to alleviate COVID-19 symptoms might be anti-inflammatory effects on SARs-CoV-2-infected lung cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AKT1-HSP90AB1-BCL2 | |
| 650 | 4 | |a Akti-1/2-HSP990-S55746 | |
| 650 | 4 | |a Anti-inflammatory effects | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Estrogen signaling pathway | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Adnan, Md |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Dong Ha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical hypotheses |d 1983 |g 155(2021) vom: 27. Okt., Seite 110656 |w (DE-627)NLM00007487X |x 1532-2777 |7 nnns |
| 773 | 1 | 8 | |g volume:155 |g year:2021 |g day:27 |g month:10 |g pages:110656 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mehy.2021.110656 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 155 |j 2021 |b 27 |c 10 |h 110656 | ||